You are here: Industry Insights > Valeant

News List

Ortho resubmits Duobrii in the US pharmatimes
August 17, 2018
Bausch Health group Ortho Dermatologics has resubmitted an application to market its plaque psoriasis lotion Duobrii in the US.
FDA rejects Valeant plaque psoriasis lotion over pharmacokinetic concerns pharmafile
June 22, 2018
Beleaguered pharma firm Valeant has come up against another bump in the road as its plaque psoriasis lotion Duobrii (halobetasol propionate and tazarotene) was rejected for US approval by the FDA.
US regulators reject Valeant’s Duobrii pharmatimes
June 21, 2018
The US Food and Drug Administration has rejected Valeant group Ortho Dermatologics’ plaque psoriasis therapy Duobrii.
Meet the new Valeant: Drugmaker drops tainted name to become Bausch Health in July rebrand fiercepharma
May 09, 2018
Market watchers and Valeant investors have seen no shortage of changes at the company during its storied collapse. Now, the drugmaker is getting a new name to press ahead...
Ono Pharma submits marketing approval of metyrosine in Japan biospectrumasia
May 03, 2018
This application is based on a multicenter, open-label, non-comparative study and its accompanying continuous administration study
Valeant teams up with Kaken for psoriasis treatment biospectrumasia
March 05, 2018
KP-470 will represent a novel drug with an alternate mechanism of action in the topical treatment of the disease
Valeant begins long comeback trail with FDA approval pharmafile
November 07, 2017
Valeant has had precious little to be happy about over the last few years, it’s bounced from one piece of bad news to another; however, it has managed a rare piece of good news after the FDA finally gave the green light for its glaucoma drug, Vyzulta.
Valeant denies bypassing eye-device maker Iconlabs in M&A bid for lens tech fiercepharma
August 18, 2017
A California company alleges Valeant's Bausch & Lomb eye business bypassed it to get technology from a partner in Turkey.
Valeant focused on bringing new products to market, receives CRL pharmafile
August 10, 2017
It revealed that it had paid down $4.8 billion on its mountain of debt since the first quarter of 2016 and CEO, Joseph Papa, said that the company would focus on launching new products, instead of selling parts of the business, to further reduce this.
Valeant cuts full-year sales forecast, as revenue drops 8 percent in second quarter firstwordpharma
August 09, 2017
Valeant Pharmaceuticals announced Tuesday that second-quarter sales fell 8 percent year-over-year to $2.2 billion, meeting analyst estimates, as revenue from branded drugs and the company's Bausch + Lomb/international segment both declined.

Previous page 1 2 3 Next page